{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:05:51Z","timestamp":1783926351288,"version":"3.55.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106244 \/Z\/14\/Z"],"award-info":[{"award-number":["106244 \/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","award":["75F40120C00085"],"award-info":[{"award-number":["75F40120C00085"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/R000344\/1"],"award-info":[{"award-number":["BB\/R000344\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/J003018\/1"],"award-info":[{"award-number":["BB\/J003018\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118995","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:14:04Z","timestamp":1779466444000},"page":"118995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cephalosporins are potent SARS-CoV-2 main protease inhibitors"],"prefix":"10.1016","volume":"316","author":[{"given":"Dorian-Gabriel","family":"Muntean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojtek","family":"Treyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"Laczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Laidlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eidarus","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0290-6565","authenticated-orcid":false,"given":"Christopher J.","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Brewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118995_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112829","article-title":"\u03b2-lactam antibiotics: an overview from a medicinal chemistry perspective","volume":"208","author":"Lima","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/br.38.3.291-335.1974","article-title":"Interaction of penicillin with the bacterial cell: penicillin-binding proteins and penicillin-sensitive enzymes","volume":"38","author":"Blumberg","year":"1974","journal-title":"Bacteriol. Rev."},{"key":"10.1016\/j.ejmech.2026.118995_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0022-2836(71)90393-7","article-title":"Conformation of penicillin as a transition-state analog of the substrate of peptidoglycan transpeptidase","volume":"61","author":"Lee","year":"1971","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118995_bib4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1073\/pnas.54.4.1133","article-title":"Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine","volume":"54","author":"Tipper","year":"1965","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118995_bib5","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1039\/D1MD00200G","article-title":"\u03b2-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates","volume":"12","author":"Mora-Ochomogo","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib6","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-Lactams and \u03b2-Lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2026.118995_bib7","series-title":"The Chemistry of \u03b2-Lactams","first-page":"129","article-title":"The mechanisms of reactions of \u00df-lactams","author":"Page","year":"1992"},{"key":"10.1016\/j.ejmech.2026.118995_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.mib.2010.09.008","article-title":"The future of the \u03b2-lactams","volume":"13","author":"Llarrull","year":"2010","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118995_bib9","series-title":"Biochemistry of Antimicrobial Action","first-page":"20","article-title":"The bacterial cell wall \u2014 a vulnerable shield","author":"Franklin","year":"1989"},{"key":"10.1016\/j.ejmech.2026.118995_bib10","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1016\/j.ejmech.2010.09.035","article-title":"2-Azetidinone \u2013 a new profile of various pharmacological activities","volume":"45","author":"Mehta","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112510","article-title":"\u03b2-Lactams as promising anticancer agents: molecular hybrids, structure activity relationships and potential targets","volume":"201","author":"Fu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib12","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.2741\/1420","article-title":"Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs","volume":"9","author":"Kuhn","year":"2004","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2026.118995_bib13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/jac\/44.6.729","article-title":"\u03b2-Lactams: variations on a chemical theme, with some surprising biological results","volume":"44","author":"Hamilton-Miller","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.118995_bib14","doi-asserted-by":"crossref","first-page":"10640","DOI":"10.1016\/j.tet.2012.07.090","article-title":"Advances in the chemistry of \u03b2-lactam and its medicinal applications","volume":"68","author":"Kamath","year":"2012","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2026.118995_bib15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/jm970701f","article-title":"SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption","volume":"41","author":"Rosenblum","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib16","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1021\/jm00038a001","article-title":"2-Azetidinones as inhibitors of cholesterol absorption","volume":"37","author":"Burnett","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib17","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/S0960-894X(02)00766-7","article-title":"6-Acylamino-penam derivatives: synthesis and inhibition of cathepsins B, L, K, and S","volume":"12","author":"Zhou","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118995_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1021\/acs.jmedchem.9b00759","article-title":"Peptide-\u03b2-lactam inhibitors of Dengue and West Nile virus NS2B-NS3 protease display two distinct binding modes","volume":"63","author":"Dra\u017ei\u0107","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib19","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/(SICI)1096-9888(199812)33:12<1246::AID-JMS743>3.0.CO;2-E","article-title":"Investigation of the covalent modification of the catalytic triad of human cytomegalovirus protease by pseudo-reversible \u03b2-lactam inhibitors and a peptide chloromethylketone","volume":"33","author":"Haley","year":"1998","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ejmech.2026.118995_bib20","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1021\/jm980131z","article-title":"\u03b2-Lactam derivatives as inhibitors of human cytomegalovirus protease","volume":"41","author":"Yoakim","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib21","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0960-894X(98)00240-6","article-title":"Inhibition of human cytomegalovirus protease No with monocyclic \u03b2-lactams","volume":"8","author":"D\u00e9ziel","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118995_bib22","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1039\/D0CC06870E","article-title":"Mass spectrometry reveals potential of \u03b2-lactams as SARS-CoV-2 Mpro inhibitors","volume":"57","author":"Malla","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.118995_bib23","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1021\/acs.jmedchem.1c02214","article-title":"Penicillin derivatives inhibit the SARS-CoV-2 main protease by reaction with its nucleophilic cysteine","volume":"65","author":"Malla","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib24","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1021\/acs.jcim.3c00282","article-title":"Targeting SARS-CoV-2 main protease: a successful story guided by an In silico drug repurposing approach","volume":"63","author":"Ambrosio","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2026.118995_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0960-894X(98)00032-8","article-title":"Design and synthesis of monocyclic \u03b2-lactams as mechanism-based inhibitors of human cytomegalovirus protease","volume":"8","author":"Borthwick","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118995_bib26","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0960-894X(03)00304-4","article-title":"3,4-Disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P2 elements for selectivity","volume":"13","author":"Setti","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118995_bib27","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1039\/D5MD00789E","article-title":"C6-Alkoxy substituted penicillins are potent non-covalently binding inhibitors of the SARS-CoV-2 main protease","volume":"16","author":"Muntean","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2024.101973","article-title":"SARS-CoV-2 replication and drug discovery","volume":"77","author":"Nazir","year":"2024","journal-title":"Mol. Cell. Probes"},{"key":"10.1016\/j.ejmech.2026.118995_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102667","article-title":"Structural biology of SARS-CoV-2 Mpro and drug discovery","volume":"82","author":"Duan","year":"2023","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2026.118995_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1039\/D3MD00493G","article-title":"On the origins of SARS-CoV-2 main protease inhibitors","volume":"15","author":"Janin","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118995_bib32","doi-asserted-by":"crossref","first-page":"34196","DOI":"10.1021\/acsomega.4c03023","article-title":"Progress in research on inhibitors targeting SARS-CoV-2 main protease (Mpro)","volume":"9","author":"Yang","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.118995_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.151","article-title":"The SARS-CoV-2 main protease (Mpro): structure, function, and emerging therapies for COVID-19","volume":"3","author":"Hu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.118995_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118995_bib35","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118995_bib36","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib37","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","article-title":"A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19","volume":"67","author":"Allerton","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib38","doi-asserted-by":"crossref","first-page":"21099","DOI":"10.1021\/acs.jmedchem.5c00754","article-title":"Discovery of the clinical candidate S-892216: a second-generation of SARS-CoV-2 3CL protease inhibitor for treating COVID-19","volume":"68","author":"Unoh","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib39","doi-asserted-by":"crossref","first-page":"11656","DOI":"10.1021\/acs.jmedchem.4c01342","article-title":"Fixing the achilles heel of pfizer's paxlovid for COVID-19 treatment","volume":"67","author":"Brewitz","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202403176","article-title":"Novel cephalosporins against the main protease of SARS CoV (Mpro O, mpro WT): molecular docking and DFT Study","volume":"9","author":"Mubarik","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.ejmech.2026.118995_bib41","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1021\/acs.oprd.7b00033","article-title":"Patent review of manufacturing routes to fifth-generation cephalosporin drugs. Part 1, ceftolozane, org","volume":"21","author":"Hughes","year":"2017","journal-title":"Process Res. Dev."},{"key":"10.1016\/j.ejmech.2026.118995_bib42","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1021\/acs.jmedchem.2c01627","article-title":"Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the nucleophilic Cysteine","volume":"66","author":"Brewitz","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib43","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1246\/nikkashi.1995.577","article-title":"Development and industrialization of new intermediate 3-Chloromethyl-\u03943-cephems for cephalosporin antibiotic synthesis","volume":"1995","author":"Taniguchi","year":"1995","journal-title":"Nippon Kagaku Kaishi"},{"key":"10.1016\/j.ejmech.2026.118995_bib46","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1021\/acsptsci.0c00216","article-title":"Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in vitro repurposing screen","volume":"4","author":"Kuzikov","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.118995_bib44","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0968-0896(03)00126-3","article-title":"TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties","volume":"11","author":"Ishikawa","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.clinthera.2012.02.025","article-title":"Ceftaroline fosamil: a cephalosporin with activity against methicillin-Resistant Staphylococcus Aureus","volume":"34","author":"Poon","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejmech.2026.118995_bib47","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1039\/D4SC01027B","article-title":"Thiophene-fused \u03b3-lactams inhibit the SARS-CoV-2 main protease via reversible covalent acylation","volume":"15","author":"Gayatri","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118995_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117603","article-title":"Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies","volume":"291","author":"Laczi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100582","article-title":"Structure-activity studies reveal scope for optimisation of ebselen-type inhibition of SARS-CoV-2 main protease","volume":"17","author":"Thun-Hohenstein","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118995_bib53","article-title":"How clavulanic acid inhibits serine \u03b2-Lactamases","volume":"25","author":"Lang","year":"2024","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.118995_bib54","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117310119","article-title":"Studies on enmetazobactam clarify mechanisms of widely used \u03b2-lactamase inhibitors","volume":"119","author":"Lang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118995_bib50","doi-asserted-by":"crossref","first-page":"16928","DOI":"10.1039\/D4SC04937C","article-title":"Structural basis of Pseudomonas aeruginosa penicillin binding protein 3 inhibition by the siderophore-antibiotic cefiderocol","volume":"15","author":"Smith","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.118995_bib51","doi-asserted-by":"crossref","first-page":"22002","DOI":"10.1073\/pnas.1013092107","article-title":"Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa","volume":"107","author":"Han","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118995_bib52","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jmb.2005.10.030","article-title":"Crystal structure of penicillin-binding protein 1a (PBP1a) reveals a mutational hotspot implicated in \u03b2-lactam resistance in Streptococcus pneumoniae","volume":"355","author":"Contreras-Martel","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118995_bib55","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1021\/jm400769b","article-title":"Assay platform for clinically relevant Metallo-\u03b2-lactamases","volume":"56","author":"van Berkel","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib56","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1021\/jo00374a045","article-title":"Preparation of ceph-3-em esters unaccompanied by \u03943\/\u03942 isomerization of the cephalosporin","volume":"51","author":"Mobashery","year":"1986","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib57","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1021\/ja01034a023","article-title":"Chemistry of cephalosporin antibiotics. XV. Transformations of penicillin sulfoxide. Synthesis of cephalosporin compounds","volume":"91","author":"Morin","year":"1969","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118995_bib58","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1021\/ja00956a051","article-title":"The total synthesis of Cephalosporin C1","volume":"88","author":"Woodward","year":"1966","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118995_bib59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/qua.560360723","article-title":"Theoretical aspects of cephalosporin isomerism","volume":"36","author":"Pop","year":"1989","journal-title":"Int. J. Quantum Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib60","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1039\/j39660001142","article-title":"Cephalosporanic acids. Part IV. 7-Acylamidoceph-2-em-4-carboxylic acids","author":"Cocker","year":"1966","journal-title":"J. Chem. Soc. C"},{"key":"10.1016\/j.ejmech.2026.118995_bib61","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1055\/s-0029-1216972","article-title":"Chemo- and product-selective electrooxidation of 3-(Arylthiomethyl)-\u03943-cephems","volume":"2009","author":"Tanaka","year":"2009","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2026.118995_bib62","first-page":"s1","article-title":"New concepts in the field of cephalosporins: C-3\u2032quaternary ammonium cephems (Group IV), Clin","volume":"3","author":"Bryskier","year":"1997","journal-title":"Microbiol. Infect."},{"key":"10.1016\/j.ejmech.2026.118995_bib63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1246\/bcsj.69.229","article-title":"Aerobic oxidation of 3-Iodomethyl-\u03943-cephem-4-carboxylate to 3-Formyl-\u03943-cephem-4-carboxylate through 3-Hydroperoxymethyl-\u03943-cephem-4-carboxylate","volume":"69","author":"Tanaka","year":"1996","journal-title":"Bull. Chem. Soc. Jpn."},{"key":"10.1016\/j.ejmech.2026.118995_bib64","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1007\/s00253-022-12272-8","article-title":"Cephalosporins as key lead generation beta-lactam antibiotics","volume":"106","author":"Lin","year":"2022","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.118995_bib65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0924-8579(00)00179-5","article-title":"Sir Edward Abraham's contribution to the development of the cephalosporins: a reassessment","volume":"15","author":"Hamilton-Miller","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2026.118995_bib66","first-page":"188","article-title":"Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime, drug","volume":"19","author":"Tartaglione","year":"1985","journal-title":"Intell. Clin. Pharm."},{"key":"10.1016\/j.ejmech.2026.118995_bib67","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01642764","article-title":"Cephamycins: a review, prospects and some original observations","volume":"3","author":"Hamilton-Miller","year":"1975","journal-title":"Infection"},{"key":"10.1016\/j.ejmech.2026.118995_bib68","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0891-5520(20)30291-9","volume":"3","author":"Donowitz","year":"1989","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.ejmech.2026.118995_bib69","doi-asserted-by":"crossref","first-page":"s87","DOI":"10.1111\/j.1469-0691.1997.tb00649.x","article-title":"Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility","volume":"3","author":"Garau","year":"1997","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejmech.2026.118995_bib70","series-title":"New Antimicrobials: for the Present and the Future","first-page":"25","article-title":"New cephalosporins: fifth and sixth generations","author":"Fong","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118995_bib71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between \u03b2-lactamases and new \u03b2-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.118995_bib72","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jmb.2004.10.076","article-title":"Crystal structures of complexes between the R61 DD-peptidase and peptidoglycan-mimetic \u03b2-lactams: a non-covalent complex with a \u201cPerfect Penicillin\u201d","volume":"345","author":"Silvaggi","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118995_bib73","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2174\/0929867322666150311150215","article-title":"The allosteric site for the nascent cell wall in penicillin-binding protein 2a: an achilles' heel of methicillin-resistant Staphylococcus aureus","volume":"22","author":"Ivan","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib74","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/carcin\/bgs283","article-title":"Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B","volume":"33","author":"Li","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2026.118995_bib75","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/bc00023a005","article-title":"Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-\u03b2-lactamase conjugates","volume":"4","author":"Vrudhula","year":"1993","journal-title":"Bioconj. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0960-894X(01)81083-0","article-title":"A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody \u03b2-lactamase conjugate for the treatment of cancer","volume":"1","author":"Shepherd","year":"1991","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118995_bib77","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1021\/jm00171a029","article-title":"Inhibition of human leukocyte elastase. 2. Inhibition by substituted cephalosporin esters and amides","volume":"33","author":"Finke","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib78","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1021\/jm00099a002","article-title":"Inhibition of human leukocyte elastase. 4. Selection of a substituted cephalosporin (L-658,758) as a topical aerosol","volume":"35","author":"Finke","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib79","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/322192a0","article-title":"Cephalosporin antibiotics can be modified to inhibit human leukocyte elastase","volume":"322","author":"Doherty","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118995_bib80","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.1016\/S0040-4020(01)80243-X","article-title":"An investigation into the mechanism of elastase inhibition by cephalosporins using electrospray ionisation mass spectrometry","volume":"49","author":"Aplin","year":"1993","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2026.118995_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174151","article-title":"A comprehensive review on pharmacology of efflux pumps and their inhibitors in antibiotic resistance","volume":"903","author":"Thakur","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118995_bib82","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/00498250701867889","article-title":"Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition","volume":"38","author":"Zhou","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejmech.2026.118995_bib83","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1021\/bi0524870","article-title":"Localization of multidrug transporter substrates within model membranes","volume":"45","author":"Siarheyeva","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.118995_bib84","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2008610118","article-title":"Competing off-loading mechanisms of meropenem from an l,d-transpeptidase reduce antibiotic effectiveness","volume":"118","author":"Zandi","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.118995_bib85","doi-asserted-by":"crossref","first-page":"16604","DOI":"10.1074\/jbc.RA120.014607","article-title":"Analysis of \u03b2-lactone formation by clinically observed carbapenemases informs on a novel antibiotic resistance mechanism","volume":"295","author":"Aertker","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202200327","article-title":"SARS-CoV-2 papain-like protease: structure, function and inhibition","volume":"23","author":"Ullrich","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2026.118995_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200016","article-title":"Mass spectrometric assays reveal discrepancies in inhibition profiles for the SARS-CoV-2 papain-like protease","volume":"17","author":"Brewitz","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.118995_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117498","article-title":"Mass spectrometric assays monitoring the deubiquitinase activity of the SARS-CoV-2 papain-like protease inform on the basis of substrate selectivity and have utility for substrate identification","volume":"95","author":"Brewitz","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib89","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118995_bib90","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600440X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600440X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:15:45Z","timestamp":1783923345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600440X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":90,"alternative-id":["S022352342600440X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118995","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cephalosporins are potent SARS-CoV-2 main protease inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118995"}}